By extrapolation, based on the time of peak BMAL1 expression in mouse xenograft models of GBM [11, 17], the model suggests TMZ should be given around CT4, corresponding to treatment in the subjective early morning. The gene discussed is BMAL1; the disease is glioblastoma.